Rapid Dose Therapeutics Corp.
DOSE.CNCNQHealthcare● Active
$0.10
$-0.01(-5.00%)
Market Cap$12529265
P/E Ratio—
52W High$0.24
52W Low$0.085
Rapid Dose Therapeutics Corp. (DOSE.CN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DOSE.CN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-02 | 2024-02 | 2023-02 | 2022-02 | 2021-02 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.09M | $1.02M | $0.72M | $1.75M | $0.76M |
| Cost of Revenue | $0.91M | $0.46M | $0.35M | $0.41M | $0.06M |
| Gross Profit | $1.18M | $0.56M | $0.37M | $1.34M | $0.70M |
| Gross Margin %(computed) | 56.59% | 55.24% | 51.85% | 76.77% | 92.67% |
| Operating Expenses | |||||
| R&D Expenses | $0.15M | $0.43M | $0.09M | $0.36M | $0.09M |
| G&A Expenses | $4.24M | $2.36M | $2.95M | $4.23M | $1.34M |
| Total Operating Expenses | ($4.22M) | $4.30M | $4.18M | $5.78M | $2.33M |
| Operating Income | $5.40M | ($3.74M) | ($3.81M) | ($4.43M) | ($1.78M) |
| Operating Margin %(computed) | 259.18% | -366.57% | -530.14% | -253.14% | -235.30% |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $1.23M | $0.66M | $0.26M | $0.13M | $0.14M |
| Income Before Tax | ($5.40M) | ($4.31M) | ($3.81M) | ($8.49M) | ($1.80M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($5.40M) | ($4.31M) | ($3.81M) | ($8.49M) | ($1.80M) |
| Net Margin %(computed) | -259.18% | -422.16% | -530.42% | -484.42% | -239.01% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.04 | $-0.04 | $-0.04 | $-0.08 | $-0.02 |
| Wtd Avg Shares | 124.57M | 104.96M | 103.42M | 100.22M | 77.79M |
| EBITDA | ($3.93M) | ($3.02M) | ($2.92M) | ($7.59M) | ($0.99M) |
| EBITDA Margin %(computed) | -188.53% | -296.57% | -406.24% | -433.11% | -130.69% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · CAD · M
Explore more Rapid Dose Therapeutics Corp. data
About Rapid Dose Therapeutics Corp. (DOSE.CN) Income Statement
Rapid Dose Therapeutics Corp. (DOSE.CN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, DOSE.CN reported revenue of $0.00B, gross profit of $0.00B (gross margin 56.59%), and net income of ($0.01B) — a net profit margin of -259.18%.
Frequently asked questions
DOSE.CN · 4 questionsRapid Dose Therapeutics Corp. (DOSE.CN) reported revenue of $0.00B for 2025, up 104.4% year-over-year.
DOSE.CN revenueDOSE.CN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08